Background . Medical management of heart failure with preserved ejection fraction (HFPEF) remains unclear. This analysis was to assess the benefit of ACE-inhibitors (ACEi) and beta blockers (BB) in patients with HFPEF and in heart failure with reduced ejection fraction (HFREF). .Methods . The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center, international study of 1,641 patients presenting with dyspnea. This is a secondary analysis of the BACH trial. .Results . Patients with a diagnosis of congestive heart failure (CHF) whom were discharged on a BB or an ACEI had improved survival in both HFPEF and HFREF. The propensity score score for being prescribed an ACEi was 0.710 and for a BB was 0.614. A model including all CHF patients and both beta blocker and ACEi, ACEi alone, and BB alone demonstrated the most protective effect with ACEi. .Conclusions . Patients with HFPEF and HFREF both demonstrate improved survival when being discharged on ACEi and BB, with ACEi possibly having more survival benefit. .
IMPROVED SURVIVAL IN PATIENTS WITH DIASTOLIC HEART FAILURE DISCHARGED ON BETA-BLOCKER AND ACE INHIBITORS / K., Shah; N., Parekh; P., Clopton; I., Anand; R., Christenson; L., Daniels; DI SOMMA, Salvatore; G., Filippatos; J., Mccord; C., Mueller; Neath, S. X.; R., Nowak; Peacock, W. F.; P., Ponikowski; S., Anker; A., Maisel. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - STAMPA. - 61 (Supplemento A):10(2013), pp. A155-A155. [10.1016/S0735-1097(13)60634-8]
IMPROVED SURVIVAL IN PATIENTS WITH DIASTOLIC HEART FAILURE DISCHARGED ON BETA-BLOCKER AND ACE INHIBITORS
DI SOMMA, Salvatore;
2013
Abstract
Background . Medical management of heart failure with preserved ejection fraction (HFPEF) remains unclear. This analysis was to assess the benefit of ACE-inhibitors (ACEi) and beta blockers (BB) in patients with HFPEF and in heart failure with reduced ejection fraction (HFREF). .Methods . The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center, international study of 1,641 patients presenting with dyspnea. This is a secondary analysis of the BACH trial. .Results . Patients with a diagnosis of congestive heart failure (CHF) whom were discharged on a BB or an ACEI had improved survival in both HFPEF and HFREF. The propensity score score for being prescribed an ACEi was 0.710 and for a BB was 0.614. A model including all CHF patients and both beta blocker and ACEi, ACEi alone, and BB alone demonstrated the most protective effect with ACEi. .Conclusions . Patients with HFPEF and HFREF both demonstrate improved survival when being discharged on ACEi and BB, with ACEi possibly having more survival benefit. .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
